XBIO vs. VT

In the year-to-date period, XBIO achieves a -30.02% return, which is significantly lower than VT's -1.11% return. Over the past 10 years, XBIO has underperformed VT with an annualized return of -44.52%, while VT has yielded a comparatively higher 8.45% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Xenetic Biosciences, Inc. (XBIO) and Vanguard Total World Stock ETF (VT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current XBIO Sharpe Ratio is -0.39, which is lower than the VT Sharpe Ratio of 0.58. The chart below compares the historical Sharpe Ratios of XBIO and VT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

XBIO has not paid dividends to shareholders, while VT's dividend yield for the trailing twelve months is around 1.95%.

The maximum XBIO drawdown since its inception was -99.94%, which is greater than VT's maximum drawdown of -50.27%. Use the drawdown chart below to compare losses from any high point for XBIO and VT. For additional features, visit the drawdowns tool.

Xenetic Biosciences, Inc. (XBIO) has a higher volatility of 26.28% compared to Vanguard Total World Stock ETF (VT) at 12.77%. This indicates that XBIO's price experiences larger fluctuations and is considered to be riskier than VT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.